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CORRESPONDENCE
Re. “The Effect of Deep Venous Stenting on Healing of
Lower Limb Venous Ulcers”
We read with interest Peter Neglen’s commentary on our
paper.1,2
The commentary raises the issue of establishing a diag-
nosis of signiﬁcant obstruction in the absence of expensive
intravascular ultrasound (IVUS) technology. Indeed, this is
the Achilles heel of deep venous disease diagnosis and
perhaps the reason for worldwide underutilization of deep
vein stenting to treat venous ulcers.
Our technique of using trial diagnostic ballooning is
advocated by Raju and Neglen,3 who demonstrated that
trial ballooning helped detect an additional 5% of patients
whose disease was “impervious to even IVUS” and standard
morphological criteria on venography.3 Our own experience
has shown that a combination of venography with selective
trial ballooning helps increase the detection rate to 91%
compared with IVUS alone.4
We agree with Dr Neglen’s comment regarding the use of
high-pressure balloons. We use only semi-compliant bal-
loons for the same reason.4 We agree completely with Dr
Neglen’s comment on the urgent need for an accurate he-
modynamic test of outﬂow obstruction.
We did not give the full CEAP classiﬁcation for all patients
because our study reported only on nonhealing ulcer-
related outcomes, which, by deﬁnition, is C6. We agree
that a reduction in ulcer size is in itself not an accepted
endpoint; however, for large, long-standing ulcers, it reﬂects
a response to therapy. The revised venous clinical severity
score would be the ideal tool to capture this.
We believe this paper reﬂects the “real-world” outcomes
of deep venous stenting for leg ulcers in centers without
access to IVUS.
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Re. ‘Endograft Limb Occlusion in EVAR: Iliac Tortuosity
Quantiﬁed by Three Different Indices on the Basis of
Pre-operative CTA’
This article was with interest at our journal club meeting
and we were delighted with its reported outcome, which
correlates endograft limb occlusion to deﬁned preoperative
iliac tortousity.1
However, there are a few points that we wish to clarify
with the authors of the article. First, this study demon-
strated that the mean  SD of common iliac artery index of
tortuosity (CAI) in patients with graft limb occlusion was
1.31  0.2, which is signiﬁcantly different from the control
group (1.16  0.13). Would the authors of the article be
able to analyse their results further to determine a cut-off
point in CAI that would deﬁne the high-risk patient
group? For example, what is the risk of endograft limb oc-
clusions in a patient with a CAI of 1.25?
It was very useful to assess simply iliac tortuosity using
the double iliac sign, which showed a signiﬁcant difference
from the control group (p < .01). It would be useful to
know the percentage of this ﬁnding in the whole cohort of
patients. And are the authors able to explain why 12% of
the control group had this sign but without endograft limb
occlusion?
We were interested to note that all patients in this study
were treated with endovascular aortic repair (EVAR) using
the Zenith stent graft (Cook Inc., Bloomington, IN, USA)
from January 2000 to December 2010. Were any newer
versions of devices used during this 10-year period and does
this inﬂuence the incidence of limb occlusion? It would be
interesting to know whether there is any particular associ-
ation or pattern that could be identiﬁed in the timing of the
EVARs that are eventually occluded.
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Response to Letter to the Editor: ‘Re: Endograft Limb
Occlusion in EVAR: Iliac Tortuosity Quantiﬁed by Three
Different Indices on the Basis of Pre-operative CTA’
We thank the group for their insightful comments and the
opportunity to clarify a number of points from our work on
endograft limb occlusion.
In our series to determine a cut-off value of common iliac
artery tortuosity index (CAI) for high-risk patients, we con-
structed a receiver operating characteristic (ROC) curve. The
area under curve was 0.72 (95% CI 0.55e0.88) with a best
cut-off value of 1.26. With CAI  1.26, the positive pre-
dictive value was 67% and the negative predictive value was
65%. The sensitivity and speciﬁcity were 59% and 85%,
respectively. The relative risk for limb occlusion was 2.8.
Our article is a cohort study, so we do acknowledge the
limitation of the chosen control group. Four patients in the
control group had double iliac sign (DIS), and two of these
had primary adjunctive stenting performed. In our series we
simply state the observation that two other patients with
DIS had their z-stent part of the graft limbs placed directly
within the most tortuous part of the vessel, therefore
having the part of the graft limb with the most radial force
where it was needed. We acknowledge this may simply be
pure speculation.
During the extended decade period 2000e2010, we used
only the Zenith ﬂex (Cook Inc, Bloomington, IN, USA) limbs.
The incidence of limb occlusions was equally distributed in
the time period.
We hope that other centres will review and publish their
survival results to provide further information, and we hope
this will provide a more robust answer to some of the
questions that have been raised.
M. Taudorf, T.V. Schroeder, L. Lönn, On behalf of the co-
authors
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Re. ‘Beneﬁts of Remote Ischemic Preconditioning
in Vascular Surgery’
We read with interest the review article of Twine et al.1 In
recent years several articles have addressed this topic and
reported various results with regard to the extent of organ
protection. In our opinion, it is to be expected that the
clinical application of this technique will encounter similar
drawbacks as we have witnessed with the concept of
ischemic and pharmacological preconditioning. Indeed,
despite the promising data from experimental studies, the
implementation of preconditioning strategies in clinical
practice was disappointing.
This apparent discrepancy between experimental and
clinical data is multifactorial but central in this is the fact that
a cardiac or vascular patient with his associated pathology
can by no means be compared to an experimentaldmostly
healthydanimal model. Associated pathology such as for
instance diabetes and concurrent medication have been
shown to interfere with the mechanisms of preconditioning.
As such, the beneﬁcial effects of these strategies may very
well be blocked by these factors.
Another key element that is frequently overlooked is the
concurrent inﬂuence of anesthetic agents. Volatile anes-
thetics have a pharmacological preconditioning effect, and,
speciﬁcally in coronary surgery, it has been shown that the
use of such agents was associated with less postoperative
myocardial damage and a better preservation of myocardial
function.2,3 Interestingly, when a remote ischemic pre-
conditioning protocol was applied on top of a volatile
anesthetic regimen, no additional protection was
observed.4 We therefore suggest that future studies and
reports take this variable into account. It is very well
possible that the absence of effect in certain remote
ischemic preconditioning protocols may be related to the
fact that the strategy was applied on top of a volatile
anesthetic based anesthesia.
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